Sign In

David Messenheimer

Immunologist, Drug Hunter

David Messenheimer is a Research Scientist IV at the University of Washington, specializing in translational immunology. He has a strong focus on developing combination immunotherapy strategies, particularly involving cancer vaccines. His research interests include understanding tumor immunity and the application of proteogenomics to identify novel cancer antigens.

Education and Experience

  • Education: Messenheimer completed his studies at Oregon Health and Science University, where he developed a solid foundation in immunology.
  • Professional Background: He is recognized for his collaborative approach in building research teams and has contributed significantly to the field through various presentations and publications. His work often involves invited talks at prestigious conferences, showcasing advancements in immunotherapy and cancer treatment strategies.123

Contributions to Immunology

Messenheimer has been actively involved in:

  • Presenting at international conferences such as the European Society for Medical Oncology (ESMO) and the National Cancer Institute (NCI).
  • Researching the efficacy of cancer vaccines and their role in combination therapies, aiming to improve patient outcomes in oncology.12

His LinkedIn profile indicates that he is inquisitive and dedicated to advancing the field of immunology through innovative research practices.2

Highlights

Mar 24 · linkedin

Wow. This technology looks so cool and the story in Rwanda that Mark Rober tells here is incredible (They're using high-tech drones to deliver blood and medical supplies to remote hospitals in Rwanda, leading to an 88% decrease in-hospital maternal mortality!).
(and full disclosure we subscribe to his CrunchLab engineering build boxes for kids and they're outstanding)

Jan 24 · linkedin

Cool paper from Carl June's group demonstrating that in mouse models, CAR-T cell off-target effects can be significantly reduced by administering the CAR-T cells in gel (fibrin glue) at the tumor resection site. Much more effective than giving CAR-T cell intravenously. They are proposing using these localized CAR-T cells to eliminate tumor cells that are not removed in the surgical margins of patients. Is there any chance this would work with antibodies or ADCs to reduce off target toxicity?

Related Questions

What are David Messenheimer's main research interests?
How has David Messenheimer contributed to cancer immunotherapy?
What are some notable presentations David Messenheimer has given?
What is the focus of David Messenheimer's work at the University of Washington?
Can you provide more details about David Messenheimer's work on combination immunotherapy?
David Messenheimer
David Messenheimer, photo 1
David Messenheimer, photo 2
Add to my network

Location

Seattle, Washington, United States